Company news

Tarsus Pharmaceuticals, Inc. news in 2026

Tarsus Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Tarsus to Participate in Upcoming Investor Conferences

November 5, 2026

Tarsus Reports Third Quarter 2026 Financial Results

November 3, 2026

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

October 29, 2026

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

October 28, 2026

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

September 29, 2026

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

September 4, 2026

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

August 6, 2026

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

August 6, 2026

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

August 6, 2026

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

August 5, 2026

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

July 13, 2026

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

July 8, 2026

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

May 6, 2026

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

April 29, 2026

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05, a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

April 1, 2026

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

March 30, 2026

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

March 22, 2026

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

February 23, 2026

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

February 18, 2026

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

February 17, 2026

Calls in 2026

Decks in 2026